ALL PRODUCTS
NO PRODUCT FOUND!
Loading ...
Total 100 products
Shandong Shengli Bioengineering Co., Ltd
Shandong Shengli Bioengineering Co., Ltd
Shandong Shengli Bioengineering Co., Ltd (Abbreviation: SHENGLI) is a joint venture built by China Animal Husbandry Industry Company Limited (Abbreviation: CAHIC) and Shandong Shengli Corporation Limited. And originally built in 2004 with total investment of RMB 500 million, and guided by bio-fermentation technology, producing animal-specific antibiotic API, veterinary preparations and feed additives. Also, it is national high-tech enterprise, and regarded as top 10 veterinary drug enterprise in Shandong province and top 10 in national veterinary drug industry in China.
Shengli is located in No.118, High-tech zone, Jining city, Shandong province, China. And it has covered an area of 70 acres, and equipped with 1st class facility as well as advanced management. Currently Shengli primarily manufactures feed additives, such as Enramycin, Bambermycin, Hainanmycin, Nosiheptide, Monensin and Salinomycin, also veterinary drugs as Tiamulin Fumarate, Florfenicol, Tilmicosin, Doxycycline Hydrochloride, etc. And Shengli is global leader on Tiamulin Fumarate and Bambermycin production and sales, also the professional manufacturer in the globe that own China self-owned intellectual property on Hainanmycin sodium API & Premix.
Shengli possesses complete veterinary drug workshop and production line that passes US FDA and CHINA GMP authentication, and there are production equipments of first-rate and high level automation that manufacture various animal-specific drugs. In strict accordance with current GMP standard in EU and USA, we have been establishing and improving quality control system, and our product have been registered and authenticated in dozens of countries and areas overseas. Among all products, Tiamulin Fumarate API has been awarded EU COS certificate in the lead; Tiamulin Fumarate Premix 80% have required Japan FMA certificate; Premix of Tiamulin Fumarate and that of Bambermycin, Monensin, Salinomycin have achieved Australia APVMA authentication. And we possess self-owned intellectual property patent in China concerning Enramycin and Avilamycin, and our products are sold well both at home and abroad.
Shengli values research and re-innovation on technology import, and set up Cahic-Shengli R&D Institute, and Shengli has required many national patent and scientific achievements while positively establishing cooperation with peers and professionals domestic and overseas.
Shengli always adhere to the management principle of [Success on quality, Sharing on profit, and all win on prosperity". We stick to contract-honoring and promise-keeping, with high brand reputation, and have built well-rounded marketing network domestic and overseas.
The PDF has been encrypted, and you need to enter the password for normal access.
We provide PDF for you to look at the catalog, and you need to provide an email address.